Core Insights - The company reported a total revenue of 757 million yuan for Q3 2025, with a net profit attributable to shareholders of 65.68 million yuan and a net cash inflow from operating activities of 104 million yuan [1]. Financial Performance - The latest asset-liability ratio stands at 30.10% [3]. - The gross profit margin is 35.59%, which is a decrease of 0.67 percentage points compared to the same period last year [3]. - The return on equity (ROE) is reported at 6.48% [3]. - The diluted earnings per share (EPS) is 0.30 yuan [3]. - The total asset turnover ratio is 0.52 times, while the inventory turnover ratio is 5.99 times [3]. Shareholder Structure - The number of shareholders is 23,900, with the top ten shareholders holding a total of 77.11 million shares, accounting for 35.28% of the total share capital [3]. - The top shareholders include: 1. Pan Weichao - 30.51% 2. Pan Zhigang - 0.91% 3. Sun Hao - 0.72% 4. Wang Guochang - 0.57% 5. Industrial and Commercial Bank of China - 0.55% 6. China Merchants Bank - 0.43% 7. China Construction Bank - 0.43% 8. Fang Yizhong - 0.41% 9. Guangdong Lexin Medical Electronics Co., Ltd. - 0.34% 10. Jiang Jinqiao - 0.34% [3].

Group 1 - The core viewpoint of the news is that LeXin Medical (300562.SZ) reported a decline in institutional ownership in its third-quarter report for 2025, with a total of 458.12 million shares held by five institutional investors, representing 2.10% of the total share capital, a decrease of 2.06 percentage points from the previous quarter [1] - Among public funds, two funds increased their holdings compared to the previous period, including a medical device ETF and Yuanxin Yongfeng Medical Health A, with an increase in holdings of 0.41% [1] - One public fund, Yuanxin Yongfeng Ju You A, reported a slight decrease in holdings compared to the previous quarter, while 85 public funds did not disclose their holdings this period, including several notable funds [1] Group 2 - From the perspective of foreign investment, Barclays Bank PLC did not disclose its holdings in this period compared to the previous quarter [2]

Group 1 - The core point of the article is that 乐心医疗 (Lifesense Medical) held its seventh board meeting on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the time of reporting, 乐心医疗 has a market capitalization of 3.1 billion yuan [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第五届董事会第七次会议审议通过了《关于<2025 年第三季度报告>的议 案》，为使投资者全面了解公司的经营情况和财务状况，公司《2025 年第三季度 报告》将于 2025 年 10 月 28 日在中国证监会指定的创业板信息披露网站巨潮资 讯网（www.cninfo.com.cn）披露，敬请投资者注意查阅。 特此公告。 广东乐心医疗电子股份有限公司 董事会 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-112 广东乐心医疗电子股份有限公司 关于2025年第三季度报告披露的提示性公告 二〇二五年十月二十八日 ...

Revenue and Profitability - Revenue for Q3 2025 was CNY 235,764,360.18, a decrease of 8.53% compared to the same period last year[9] - Net profit attributable to shareholders increased by 49.20% to CNY 23,390,957.76 for Q3 2025[9] - Basic earnings per share rose by 49.03% to CNY 0.1076 for Q3 2025[9] - Total operating revenue for the current period reached ¥757,129,146.52, a slight increase from ¥756,340,201.33 in the previous period[26] - Net profit for the current period reached CNY 64,762,159.33, an increase of 34.3% compared to CNY 48,186,091.31 in the previous period[27] - Basic and diluted earnings per share increased to CNY 0.3020 from CNY 0.2329, reflecting a growth of 29.7%[28] - The company reported a total comprehensive income of CNY 64,038,197.69, up from CNY 48,305,724.46, indicating a growth of 32.6%[27] - Operating profit for the current period was CNY 68,426,189.91, an increase of 37.9% from CNY 49,553,013.12 in the previous period[27] Assets and Liabilities - Total assets decreased by 6.15% to CNY 1,419,728,596.71 compared to the end of the previous year[9] - Cash and cash equivalents decreased significantly to ¥501,394,898.07 from ¥764,004,671.27, indicating a reduction of approximately 34.4%[24] - Current liabilities decreased to ¥410,572,565.66 from ¥516,910,915.56, a reduction of approximately 20.5%[25] - Non-current liabilities decreased to ¥16,741,131.35 from ¥19,342,240.67, showing a decline of about 13.4%[25] - The company's total equity increased to ¥992,414,899.70 from ¥976,513,797.66, representing a growth of approximately 1.6%[26] Cash Flow - Cash flow from operating activities increased by 39.68% to CNY 104,361,923.95 year-to-date[15] - Cash flow from operating activities generated a net amount of CNY 104,361,923.95, up from CNY 74,715,336.81, representing a 39.6% increase[28] - Cash flow from investing activities resulted in a net outflow of CNY 214,816,891.41, an improvement from the previous period's outflow of CNY 373,077,081.51[29] - Cash and cash equivalents at the end of the period totaled CNY 458,397,813.03, compared to CNY 290,653,811.84 at the end of the previous period, an increase of 57.8%[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,850[17] - The largest shareholder, Pan Weichao, holds 30.56% of shares, totaling 66,802,874 shares, with 18,710,000 shares pledged[17] - The total number of restricted shares held by Pan Weichao is 54,050,155, which are subject to executive lock-up[20] - The company repurchased 912,200 shares, accounting for 0.42% of the total share capital[18] - The top ten shareholders include various institutional investors, with the largest institutional holding being 0.55%[17] - The total number of shares held by the top ten unrestricted shareholders is 12,752,719 shares for Pan Weichao[18] - The company has not disclosed any changes in the status of preferred shareholders or their holdings[19] Strategic Initiatives - The company has implemented a stock option incentive plan and employee stock ownership plan for 2025, with profit targets set at RMB 80 million and RMB 100 million for 2025 and 2026 respectively[21][22] - The company aims to align the interests of shareholders, management, and core employees through the new incentive plans[22] - The report indicates that the company is focused on long-term development and achieving strategic goals[22] Inventory and Costs - The company’s inventory decreased by 30.73% to CNY 66,629,867.62, attributed to revenue realization from previous stock[13] - Total operating costs decreased to ¥685,490,345.42 from ¥698,416,206.35, with operating costs specifically at ¥487,684,162.71 compared to ¥482,104,867.66 previously[26] - The company’s inventory decreased to ¥66,629,867.62 from ¥96,190,264.83, reflecting a reduction of approximately 30.8%[24] - Research and development expenses were reported at ¥70,314,459.02, down from ¥74,604,037.68, indicating a decrease of about 5.8%[26] Investment Income - Investment income surged by 566.42% to CNY 4,331,584.38 in Q3 2025[14] - The company reported an investment income of ¥4,331,584.38, a significant increase from ¥649,977.75 in the previous period[26]

乐心医疗 2025 年公告 2、本次会议应到董事 7 人，实到董事 7 人。会议由董事长潘伟潮先生主持， 公司全体高级管理人员列席了本次会议。 3、本次会议的召集及召开程序符合《中华人民共和国公司法》等相关法律 法规和《公司章程》有关规定，表决形成的决议合法、有效。 二、董事会会议审议情况 本次会议以书面记名投票方式进行表决，经与会董事认真审议通过以下决议： 审议通过《关于<2025 年第三季度报告>的议案》 证券代码：300562 证券简称：乐心医疗 公告编号：2025-113 广东乐心医疗电子股份有限公司 第五届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、广东乐心医疗电子股份有限公司（以下简称"公司"）第五届董事会第 七次会议于 2025 年 10 月 17 日以电子邮件、电话、专人送达等方式通知全体董 事，会议于 2025 年 10 月 24 日在公司会议室以通讯方式召开。 三、备查文件 乐心医疗 2025 年公告 董事会 二〇二五年十月二十八日 1、广东乐心医疗电子股份有限公司第五届董事会第七次 ...

乐心医疗 2025 年公告 广东乐心医疗电子股份有限公司（以下简称"公司"）分别于 2025 年 9 月 9 日、2025 年 9 月 29 日召开第五届董事会第五次会议与 2025 年第三次临时股东 会审议通过了《关于<"增益 1 号"员工持股计划（草案）>及其摘要的议案》 等议案，同意公司通过二级市场购入标的股票的方式实施"增益 1 号"员工持股 计划（以下简称"本员工持股计划"）。具体详见公司分别于 2025 年 9 月 11 日、 2025 年 9 月 29 日披露在巨潮资讯网（www.cninfo.com.cn）的相关内容。 根据《关于上市公司实施员工持股计划试点的指导意见（2025 年修订）》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2025 年修订）》等相关规定，上市公司实施员工持股计划股票来源于二级市 场购买的，应当在股东会审议通过员工持股计划后六个月内每月公告一次购买股 票的时间、方式、数量、价格等具体情况。现将公司本员工持股计划实施进展情 况公告如下： 截至本公告披露日，公司正在积极推进本员工持股计划相关工作，尚未开始 从二级市场购入本公司股票。 广东乐 ...

广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开的第四届董事会第二十二次会议、第四届监事会第十九次会议以及 2025 年 4 月 18 日召开的 2024 年年度股东大会审议通过了《关于使用闲置募集资金进 行现金管理的议案》，同意公司使用额度不超过人民币 18,000 万元的闲置募集 资金购买安全性高、流动性好、有保本约定的商业银行的理财产品，期限自公司 股东大会审议通过之日起 12 个月内有效，在该额度内，资金可以滚动使用。相 关内容详见公司 2025 年 3 月 29 日及 2025 年 4 月 18 日刊载于巨潮资讯网 （www.cninfo.com.cn）的相关公告。 根据上述决议，公司近日在广发银行股份有限公司（以下简称"广发银行"） 办理了使用部分闲置募集资金进行现金管理的相关业务，现就具体情况公告如下： 二、审批程序 《关于使用闲置募集资金进行现金管理的议案》已经公司第四届董事会第二 十二次会议、第四届监事会第十九次会议及 2024 年年度股东大会审议通过，监 乐心医疗 2025 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2025-110 ...

Group 1 - The core point of the article is that 乐心医疗 (Lixun Medical) held its fifth board meeting on October 9, 2025, to discuss the stock option incentive plan for its employees [1] - For the first half of 2025, the revenue composition of 乐心医疗 is as follows: home medical products accounted for 66.29%, electronic health scales for 24.17%, others for 7.55%, and wearable fitness bands for 1.99% [1] - As of the report date, 乐心医疗 has a market capitalization of 3.1 billion yuan [1]

北京世辉（深圳）律师事务所 关于广东乐心医疗电子股份有限公司 2024 年股票期权激励计划行权价格调整的 关于广东乐心医疗电子股份有限公司 2024 年股票期权激励计划行权价格调整的 法律意见书 二〇二五年十月 北京世辉（深圳）律师事务所 3. 对于出具本法律意见书至关重要而又无法得到独立证据支持的事实，本 所依赖于有关政府部门、公司或者其他有关单位出具的说明或证明文件出具法律 意见。 法律意见书 致：广东乐心医疗电子股份有限公司 北京世辉（深圳）律师事务所（以下简称"本所"）接受广东乐心医疗电子股 份有限公司（以下简称"乐心医疗"或"公司"）的委托，作为公司2024年股票期权 激励计划（以下简称"本次激励计划"）的专项法律顾问，根据《中华人民共和 国公司法》《中华人民共和国证券法》（以下简称《证券法》）、中国证券监督 管理委员会《上市公司股权激励管理办法》（以下简称《管理办法》）、深圳证 券交易所（以下简称"深交所"）《深圳证券交易所上市公司自律监管指南第1 号——业务办理》等有关中国法律、行政法规、部门规章、规范性文件和深交所 的相关业务规则（以下简称"适用法律"）以及《广东乐心医疗电子股份有限公司 章程 ...